Kura Oncology price target raised to $30 from $29 at BofA

BofA raised the firm’s price target on Kura Oncology (KURA) to $30 from $29 and keeps a Buy rating on the shares. While the firm thought “there was a lot to like about Komzifti’s launch feedback,” it adds that it thinks “investors were looking for more.” With the market likely to be shared and not “winner-take-all” along with signals Komzifti’s safety, convenience, and combinability are resonating, the firm would argue that Q4 updates “strengthen the story,” the analyst tells investors.